ClinicalTrials.gg
CompletedNCT03973775Updated Oct 23, 2020

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

A Phase 3 interventional study of Permethrin Cream 5% in Scabies, sponsored by Saptalis Pharmaceuticals LLC. Completed at 5 sites in United States. Open to participants aged 2 Months to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-23.

Sponsored by Saptalis Pharmaceuticals LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2018, 7 years 11 months ago, and no results have been posted to the registry.
  • Registered 1 year 1 month after the study started (first participant enrolled Apr 2018, registered May 2019).
Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
2 Months to 65 Years
Sex
All
01

Study summary

This phase III study was conducted to establish the clinical bioequivalence of Permethrin Cream 5% and Elimite™ in the treatment of scabies following a single application.

Read the detailed description

A Double Blind, Two Arm, Multicenter, Randomized, Parallel Group Bioequivalence Study with Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of, Permethrin Cream 5% (Manufactured by Saptalis Pharmaceuticals, LLC) \& Elimite™ (Permethrin Cream 5%, manufactured for Prestium Pharma, Inc.) in Subjects with Scabies.

The objectives of this study are:

Primary Objective: To establish the clinical bioequivalence of Permethrin Cream 5% (manufactured by Saptalis Pharmaceuticals, LLC) and Elimite™ (Permethrin Cream 5%, manufactured for Prestium Pharma, Inc.) in the treatment of scabies (Sarcoptes scabiei) following a single application.

Secondary Objective: To compare the safety and tolerability between the study drugs.

02

Conditions studied

  • Scabies

Browse trials for

03

In context

Scabies

51 studies on the registry are indexed under Scabies; 10 are open to participants now.

This study's enrollment of 126 is below the median of 183 across 41 interventional studies indexed under Scabies.

Browse Scabies studies →

Lead sponsor

Saptalis Pharmaceuticals LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects and/or parent/guardian must have understood and signed appropriately administered /assent in their own language
  • Healthy male and non-pregnant/non-lactating female subjects aged 2 months to 65 years diagnosed with scabies
  • Must have dermatological evidence of active scabies (burrows, erythematous papules, etc.) confirmed by recovery of live Sarcoptes scabiei (the Principal investigator or trained and experienced Study Team examines the specimen(s) under magnification to verify the identity and viability of the scabies mite, ova, or mite feces at the site)
  • The youngest subject (with scabies infestation as defined above) from each household is considered the index or primary subject of the household for evaluation of the primary endpoint. Other members of the household and close contacts are enrolled in the study as Secondary subjects and evaluated for all safety parameters (not included in primary endpoint analysis). Secondary subjects that are confirmed to have dermatological evidence of scabies should receive the same study treatment as the Index subject
  • Must be available and willing to report for follow up visits
  • Is otherwise healthy, well-nourished, non-febrile and not suffering from an infection likely to require systemic antibiotic or topical therapy. These criteria will be ascertained during screening by the Principal investigator
  • Must agree not to use other scabicides or other medications likely to affect the evaluation of their response to scabies treatment
  • If female of , willing to use an acceptable method of , should be stable for 3 months prior to screening and throughout the study
  • Must be willing to follow the procedures to decrease infestation: Clothes and bed linens that were in contact with the subjects, their household members and close contacts during the previous 48 to 72 hours will be machine washed at 60°C and machine dried the day after the first treatment. For materials that cannot be laundered, insecticide powder or aerosolized insecticide may be used, or the items may be kept in a sealed bag for at least 48 to 72 hours.

Exclusion criteria

Exclusion Criteria:

  • Subject or parent/guardian has not signed /assent
  • Pregnant females, lactating females or females planning for a pregnancy
  • Females of who do not agree to utilize an adequate method of
  • Known history of irritation or sensitivity to parasiticides
  • Skin conditions that could make it difficult to evaluate the extent of an infestation or would present a problem in the evaluation of response to therapy (e.g. atopic dermatitis, eczema, contact dermatitis, lichen planus, papular urticaria, seborrheic dermatitis).
  • Use within 4 weeks of baseline visit (1) immunomodulators (2) systemic medications that suppress the immune system (3) topical or oral parasiticides.
  • Use within 2 weeks of baseline visit (1) topical (2) topical or systemic antibiotics
  • Has crusted scabies • Known allergy or to permethrin, any synthetic pyrethroid or pyrethrin, plants in the Asteraceae/Compositae family (e.g. chrysanthemums, ragweed, marigolds, and daisies)
  • Subjects whose household members and close contacts refuse treatment.
  • Subjects with greater than 5 infested household members and close contacts
  • Subjects whose sexual contacts do not agree to restrict prolonged skin to skin contact with non-household members during the study period
  • Subjects with a household member less than 2 months of age
  • Suffers from a renal or hepatic impairment
  • Has been treated for scabies by any form of scabies treatment whether prescription, over-the-counter or a home remedy within a month prior to their screening visit
  • Had received or used an new drug within the month immediately preceding the screening
  • Is receiving any medication likely to mask or modify scabies
  • Will not be available for follow up visits
  • Has other cutaneous conditions which might be confused with scabies
  • Seriously immune suppressed subjects
  • Has been previously empaneled in this study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Test Drug Treatment Arm

    Permethrin Cream 5%, Saptalis Pharmaceuticals, LLC

    Drug: Permethrin Cream 5%

  • Active comparator
    Reference Drug Treatment Arm

    Elimite™ (Permethrin Cream 5%), Prestium Pharma, Inc.

    Drug: Permethrin Cream 5%

Interventions

  • Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the proportion of index subjects in the Per Protocol (PP) population in each treatment group with treatment cure when examined at Visit 4 (Day 28 ± 2 Days).

    Cure is defined as demonstration of clinical cure (all clinical findings have completely resolved, including inflammatory/non-inflammatory lesions) and microscopic cure (demonstration of the absence of mites, ova, and/or mite feces) on Day 28. Negative microscopy can be declared if no mites, ova, or mite feces is found from a minimum of 3 skin scrapings from previously affected sites.

    Time frame: Day 28 ± 2 Days

07

Study locations

5 sites
  • Universal Biopharma Research Institute Inc.
    Dinuba, California 93618, United States
  • Long Beach Clinical Trials Services, Inc.
    Long Beach, California 90806, United States
  • Havana Research Institute
    Pasadena, California 91105, United States
  • SouthCoast Research Center, Inc (Clinical Site & Drug Shipment Facility)
    Miami, Florida 33136, United States
  • West Houston Clinical Research Service
    Houston, Texas 77055, United States
08

References and documents

Publications

  • Goldust M, Babae Nejad S, Rezaee E, Raghifar R. Comparative trial of permethrin 5% versus lindane 1% for the treatment of scabies. J Dermatolog Treat. 2013 Jan 20. doi: 10.3109/09546634.2012.723122. Online ahead of print. PubMed 22905702 ↗
  • Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E; 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis. 2005 Oct 19;5:88. doi: 10.1186/1471-2334-5-88. PubMed 16236177 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03973775
Lead sponsor
Saptalis Pharmaceuticals LLC
Collaborators
bioRASI, LLC
Responsible party
Sponsor
First posted
Jun 4, 2019
Start date
Apr 10, 2018
Primary completion
Nov 13, 2018
Completion
Dec 6, 2018
Last update
Oct 23, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Permethrin

Start the discussion